Know Cancer

forgot password

A Randomized, Double-blind, Placebo Controlled, Multicentre, Phase II Study of Oral Lapatinib in Combination With Concurrent Radiotherapy and Cisplatin Versus Radiotherapy and Cisplatin Alone, in Subjects With Stage III, IVA, B Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 2
18 Years
Open (Enrolling)
Neoplasms, Head and Neck, Cancer

Thank you

Trial Information

A Randomized, Double-blind, Placebo Controlled, Multicentre, Phase II Study of Oral Lapatinib in Combination With Concurrent Radiotherapy and Cisplatin Versus Radiotherapy and Cisplatin Alone, in Subjects With Stage III, IVA, B Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Inclusion Criteria

Inclusion criteria:

- Willing and able to sign a written informed consent;

- Histologically confirmed diagnosis of SCCHN of one or more of the following sites:

oral cavity, oropharynx, hypopharynx and larynx;

Multiple primary tumours will:

Have to be histologically proven; Have to be anatomically distant and surrounded by normal
tissue; Exclude distant metastasis.

- Prior to enrolment subjects must have ErbB1 over-expression determined by
immunohistochemistry (IHC) 3+ as assessed by a central laboratory;

- Subjects with stage III and IVA/IVB disease, who are to receive cisplatin
chemotherapy and radiation therapy as primary treatment (total dose 65 - 70 Gy);
Subjects with any Tis, T1 or T2 disease regardless of N stage, are excluded. Subjects
with distant metastases, ie Stage IVC, are excluded.

- Willing and able to have a tumour biopsy taken at screening; For patients who have
had prior tumour biopsy, an adequate archived specimen must be available.

- Male or female ≥18 years of age;

Criteria for female subjects or female partners of male subjects:

Non-child-bearing potential (i.e., women with functioning ovaries who have a
GM2005/00448/00 CONFIDENTIAL EGF105884 22 current documented tubal ligation or
hysterectomy, or women who are postmenopausal); Child-bearing potential (i.e., women with
functioning ovaries and no documented impairment of oviductal or uterine function that
would cause sterility.) This category includes women with oligomenorrhoea (severe), women
who are perimenopausal, and young women who have begun to menstruate. These subjects must
have a negative serum pregnancy test at screening and agree to one of the following:
Complete abstinence from intercourse from 2 weeks prior to administration of the first
dose of study medication until 28 days after the final dose of study medication; or
Consistent and correct use of one of the following acceptable methods of birth control:
male partner who is sterile prior to the female subject's entry into the study and is the
sole sexual partner for that female subject; implants of levonorgestrel; injectable
progestogen; any intrauterine device (IUD) with a documented failure rate of less than

1% per year; oral contraceptives (either combined or progestogen only); or barrier
methods, including diaphragm or condom with a spermicide.

- ECOG performance status 0, 1 or 2;

- Subjects must have adequate haematological, renal and hepatic function; Calculated
creatinine clearance ≥50 ml/min as determined by the modified method of Cockcroft and
Gault or by the EDTA method. Absolute neutrophil count ≥1,500/μl, platelets
≥100,000/μl. Haemoglobin ≥9gm/dL (5mmol/L). Aspartate (AST) and alanine transaminase
(ALT) less than 4 times the upper limit of the normal range (ULN). Total bilirubin
≤2.0 mg/dL.

- Left ventricular ejection fraction (LVEF) within the institutional normal ranges as
measured by echocardiogram (ECHO) or Multigated Acquisition (MUGA) scan;

- Able to swallow tablets whole or swallow a suspension of tablets dissolved in water
at study inclusion; The use and timing of feeding tube is optional. If necessary, the
suspension may be administered via percutaneous endoscopic gastrostomy (PEG),
percutaneous jejunostomy tube (J- Tube), or a nasogastric tube (NG or Dobhoff type

- Life expectancy of at least 6 months in the best judgment of the investigator.

Exclusion criteria:

- Nasopharyngeal, paranasal sinuses or nasal cavity tumours;

- Any prior or current treatment for invasive head and neck cancer of any kind. This
will include but is not limited to: prior tyrosine kinase inhibitors, prior
neoadjuvant therapy, prior surgical resection, or use of any investigational agent;

- Concurrent use of CYP3A4 inducers or inhibitors. A standard 3-day course of
dexamethasone for the prevention of cisplatin-induced nausea and vomiting is

- Subjects with known history of uncontrolled or symptomatic angina, arrhythmias, or
congestive heart failure;

- History of another malignancy within the last 5 years, with the exception of
completely resected basal or squamous cell skin cancer, or successfully treated
in-situ carcinoma. History of non-invasive lesion or in-situ carcinoma, including in
the head and neck region that was successfully treated with surgery, photodynamics or
laser, will be permitted;

- Peripheral neuropathy ≥ grade 2;

- Pregnant or lactating females (female subjects of child-bearing potential will
undertake pregnancy testing at screening and during study completion/withdrawal

- Malabsorption syndrome, disease significantly affecting GI function, that could
affect absorption of lapatinib;

- History of allergic reactions to appropriate antiemetics (e.g. 5-HT3 antagonists) to
be administered with platinum chemotherapy;

- The investigator considers the subject unfit for the study as a result of the medical
interview, physical examinations, or screening investigations;

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

Complete response rate (as assessed by RECIST criteria) at six months after completion of chemoradiation treatment

Outcome Time Frame:

Six months post chemoradiation treatment

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:




Start Date:

November 2006

Completion Date:

August 2013

Related Keywords:

  • Neoplasms, Head and Neck
  • Cancer
  • Neck Cancer
  • Head and Neck cancer
  • Head Cancer
  • Locally advanced head and neck cancer
  • locally advanced
  • lapatinib
  • EGFR/ErbB2 inhibitor
  • Neoplasms
  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms



GSK Investigational Site Duluth, Minnesota  55805
GSK Investigational Site St. Louis, Missouri  63141
GSK Investigational Site Raleigh, North Carolina  27609